Peptide CYP9
Peptide CYP9 is a head-to-tail cyclic peptide derived from Antimicrobial peptide YD (HY-P11913). Peptide CYP9 inhibits the activation of the TGF-β/Smad signaling pathway, including the phosphorylation of Smad2/3. Peptide CYP9 inhibits the activation of the MAPK signaling pathway, including the phosphorylation of ERK and p38. Peptide CYP9 inhibits epithelial-mesenchymal transition. Peptide CYP9 inhibits extracellular matrix synthesis. Peptide CYP9 can be used for the research of pulmonary fibrosis.
For research use only. We do not sell to patients.
- CAS No.: 3124554-07-7
- Formula: C29H47N9O10
- Molecular Weight:681.74
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
Smad3 |
Smad2 |
Cyclic peptide CYP9 (up to 80 h) exhibits significantly improved serum stability in mouse serum, with a half-life of 70.17 h[1].
Cyclic peptide CYP9 (25-50 nM; 1 h) suppresses activation of the TGF-β/Smad and MAPK signaling pathways in TGF-β1-stimulated NIH-3T3 mouse fibroblasts by inhibiting phosphorylation of Smad2/3, ERK, and p38[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:TGF-β1-stimulated NIH-3T3 mouse fibroblasts
-
Concentration:25 nM; 50 nM
-
Incubation Time:24 h
-
Result:Significantly downregulated protein levels of α-smooth muscle actin (α-SMA), collagen I, and fibronectin at 25 nM and 50 nM.
| Species | Dose | Route | T1/2 | AUC0-t | AUC0-∞ | Vd | MRT |
|---|---|---|---|---|---|---|---|
| Mice[1] | 2.5 mg/kg | i.v. | 0.2098 h | 1.5330 μg·h/mL | 1.5995 μg·h/mL | 9.4627 mL | 0.2883 h |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice[1]
-
Dosage:0.02 mg/kg; 0.2 mg/kg
-
Administration:i.p.; daily; 21 days
-
Result:Significantly reduced mouse pulmonary coefficient.
Improved lung function including increased minute ventilation and greater reduction in airway resistance (Penh) compared to YD.
Downregulated protein levels of fibrotic markers α-smooth muscle actin (α-SMA), collagen I, fibronectin, and vimentin, and upregulated epithelial marker E-cadherin in lung tissue at both 0.02 mg/kg and 0.2 mg/kg doses.
Reduced mRNA expression of fibrotic markers.
Suppressed lung inflammation and fibrosis formation, with lower Ashcroft scores and reduced positive staining areas for collagen I, α-SMA, fibronectin, and Masson's trichrome fibrosis compared to BLM controls.
Inhibited BLM-induced activation of the TGF-β/Smad and MAPK signaling pathways in lung tissue, reducing phosphorylation of Smad2/3, ERK, and p38, and lowering TGF-β1 protein levels.
Chemical Information
-
CAS No. 3124554-07-7
-
Molecular Weight 681.74
-
Formula C29H47N9O10
-
Sequence
Cyclo(Lys-Gly-Val-{d-Glu}-Gly-Pro-{βAsp-amide})
-
Sequence Shortening
Cyclo(KGV-{d-Glu}-GP{βAsp-amide})
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Peptide CYP9 Related Classifications
HY-P11914 Related Classifications
Powered by Bioz
- Peptide CYP9
- 3124554-07-7
- Peptide CYP 9
- Peptide CYP-9
- Drug Derivative
- TGF-beta/Smad
- p38 MAPK
- ERK
- myofibroblast activation
- extracellular matrix synthesis
- pulmonary fibrosis
- epithelial-mesenchymal transition
- Smad2/3
- MAPK signaling pathway
- TGF-β/Smad signaling pathway
- NIH-3T3 mouse fibroblasts
- p38
- Inhibitor
- inhibitor
- inhibit